Oxidized Alpha-1-Antitrypsin as a Potential Biomarker Associated with Onset and Severity of Chronic Obstructive Pulmonary Disease in Adult Population
| Autor: | V. Milovanovic, Aleksandra Topic, Dragica Radojkovic, Z. Lazic, A. Ivosevic |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Male medicine.medical_specialty Alpha (ethology) Disease medicine.disease_cause Gastroenterology oxidized alpha-1-antitrypsin Severity of Illness Index Statistics Nonparametric 03 medical and health sciences Pulmonary Disease Chronic Obstructive 0302 clinical medicine Internal medicine alpha 1-Antitrypsin Deficiency medicine Humans Clinical significance specific inhibitor activity to elastase Aged COPD Analysis of Variance biology business.industry Chronic obstructive pulmonary disease Elastase Smoking Middle Aged medicine.disease 3. Good health respiratory tract diseases specific inhibitor activity to trypsin Oxidative Stress 030104 developmental biology 030228 respiratory system Pulmonary Emphysema Neutrophil elastase Case-Control Studies alpha 1-Antitrypsin biology.protein behavior and behavior mechanisms Biomarker (medicine) Female business Leukocyte Elastase Serbia Oxidative stress Biomarkers |
| Zdroj: | COPD-Journal of Chronic Obstructive Pulmonary Disease |
| ISSN: | 1541-2563 |
| Popis: | Oxidative stress could reduce inhibitor activity of the alpha-1-antitrypsin (A1AT). Oxidative-modified A1AT (oxidized alpha-1-antitrypsin, OxyA1AT) significantly loses ability to protect the lungs from neutrophil elastase. We aimed to investigate OxyA1AT as a potential biomarker associated with onset and severity of chronic obstructive pulmonary disease (COPD) in adult population. The study included 65 patients with COPD (33 smokers and 32 no-smokers) and 46 healthy participants (17 smokers and 29 no-smokers). Determination of OxyA1AT in serum was based on the difference between the inhibitory activities of normal and oxidized A1AT against trypsin and elastase. The level of OxyA1AT was significantly increased in the group of COPD smokers compared to healthy no-smokers (p = 0.030) and COPD no-smokers (p = 0.009). The highest level of OxyA1AT was found in group of smokers with severe and very severe COPD in comparison to the following: no-smokers with the same stage of disease (p = 0.038), smokers with moderate COPD (p = 0.022), and the healthy control group, regardless of the smoking status (control no-smokers p = 0.001 and control smokers p = 0.034). In conclusion, serum level of OxyA1AT would be potentially good biomarker for the assessment of harmful effect of smoking to the onset and severity of COPD. Also, clinical significance of OxyA1AT as prognostic biomarker could be useful in assessing the effectiveness of antioxidant therapy for COPD and emphysema. Suitable and inexpensive laboratory method for determination of OxyA1AT is additional benefit for the introduction of OxyA1AT into routine clinical practice for diagnosis and monitoring of COPD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|